Published January 1, 2022
| Version v1
Journal article
Open
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2
Creators
- Tasli, Neslihan Pakize1
- Gonen, Zeynep Burcin2
- Kirbas, Oguz Kaan1
- Gokdemir, Nur Seda2
- Bozkurt, Batuhan Turhan1
- Bayrakci, Buse1
- Sagrac, Derya1
- Taskan, Ezgi1
- Demir, Sevda1
- Gurcan, Nur Ekimci3
- Bilgic, Melike Bayindir3
- Bayrak, Omer Faruk3
- Yetiskin, Hazel
- Kaplan, Busra
- Pavel, Shaikh Terkis Islam
- Dinc, Gokcen4
- Serhatli, Muge5
- Cakirca, Gamze
- Eken, Ahmet
- Aslan, Vedat6
- Aslan, Vedat6
- 1. Yeditepe Univ, Fac Engn, Istanbul, Turkey
- 2. Erciyes Univ, Genome & Stem Cell Ctr, Oral & Maxillofacial Surg, Kayseri, Turkey
- 3. Yeditepe Univ, Fac Med, Istanbul, Turkey
- 4. Erciyes Univ, Fac Med, Kayseri, Turkey
- 5. Sci & Technol Res Council Turkey TUBITAK, Marmara Res Ctr, Energy Inst, Kocaeli, Turkey
- 6. Antalya Training & Res Hosp, Antalya, Turkey
Description
The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.
Files
bib-e2cde526-7399-4e8d-b827-b3dd90e25c6c.txt
Files
(403 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:49c358a774c5aba16ba6657af3be9ea6
|
403 Bytes | Preview Download |